<DOC>
	<DOC>NCT03045406</DOC>
	<brief_summary>Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study</brief_summary>
	<brief_title>Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
	<criteria>Consecutive patients with a newly diagnosed, objectively confirmed: symptomatic or unsuspected, proximal lowerlimb DVT or symptomatic PE or unsuspected PE in a segmental or more proximal pulmonary artery; Any type of cancer (other than basalcell or squamouscell carcinoma of the skin, primary brain tumor or intracerebral metastasis and acute leukemia); Signed and dated informed consent of the patient, available before the start of any specific trial procedure. age &lt;18 years; ECOG Performance Status III or IV; life expectancy of less than 6 months; Related to anticoagulant treatment: administration of therapeutic doses of LMWH, fondaparinux, or unfractionated heparin (UFH) for more than 72 hours before randomization; 3 or more doses of a vitamin K antagonist before randomization; thrombectomy, vena cava filter insertion, or thrombolysis used to manage the index episode; indication for anticoagulant treatment for a disease other than the index VTE episode; Related to bleeding risk: thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) or aspirin over 165 mg daily or dual antiplatelet therapy; active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; recent (in the last 1 month prior to randomization) brain, spinal or ophthalmic surgery hemoglobin level lower than 8 g/dL (5.0 mmol/L) or platelet count &lt;75x10^9/L or history of heparin induced thrombocytopenia; creatinine clearance &lt; 30 ml /min based on the Cockcroft Gault equation; acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase level 3 times or more and/or bilirubin level 2 times or more higher the upper limit of the normal range; uncontrolled hypertension (systolic BP&gt; 180 mmHg or diastolic BP &gt; 100 mmHg despite antihypertensive treatment); concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 and PGlycoprotein; Standard criteria: bacterial endocarditis; hypersensitivity to the active substance or to any of the excipients of study drug; patients participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system; childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>